Xylem Operating Cash Flow decreased by 80.1% to $108.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 227.3%, from $33.00M to $108.00M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 23.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $232.00M | $112.00M | $220.00M | -$81.00M | $113.00M | $202.00M | $362.00M | -$19.00M | $28.00M | $373.00M | $455.00M | $89.00M | $288.00M | $311.00M | $575.00M | $33.00M | $305.00M | $360.00M | $543.00M | $108.00M |
| QoQ Change | — | -51.7% | +96.4% | -136.8% | +239.5% | +78.8% | +79.2% | -105.2% | +247.4% | >999% | +22.0% | -80.4% | +223.6% | +8.0% | +84.9% | -94.3% | +824.2% | +18.0% | +50.8% | -80.1% |
| YoY Change | — | — | — | — | -51.3% | +80.4% | +64.5% | +76.5% | -75.2% | +84.7% | +25.7% | +568.4% | +928.6% | -16.6% | +26.4% | -62.9% | +5.9% | +15.8% | -5.6% | +227.3% |